Science Abstracts
Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD
October 2008
October 2008
Authors : Jessica R Philpott1 , Philip B Miner1,2
Affliation :
1University of Oklahoma Department of Digestive Diseases, Oklahoma City, OK, USA
†2Oklahoma Foundation for Digestive Research, Health Sciences Center, 1000 N. Lincoln Blvd, Ste. 210, Oklahoma City, OK 73104, USA ; ; Jennifer-mackey@ouhsc.edu
DOI : 10.1517/14712598.8.10.1627
Published in : Expert Opin. Biol. Ther. Volume 8 Issue 10 2008 pages 1627 1632
Subject:
Keywords: alicaforsen , antisense oligodeoxyribonucleotides , Crohn's disease , ICAM-1 , immunosuppressive agents , inflammatory bowel disease , ISIS 2302 , pouchitis , ulcerative colitis
Abstract
Please Login to read the full article.
RELATED CONTENT
NEWS
- Gilead's $375 million Calistoga buy signals shift into oncology and inflammation
- US Capitol Capsule: Hope not enough for Avastin in MBC; Hamburg explains withdrawal
- Amira asset DP2 blockers spun out, not part of BMS $325 million buyout
- US Capitol Capsule: Obama wants one-stop shop for patents, trade & small biz aid
COMMENT
Other Informa Comment
FEATURES
- DKSH highlights one-stop benefits as it builds Asia market expansion services
- Merck BioVentures: where biosimilars make a difference
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
